ReviewThe International journal of developmental biology2010
Challenges and strategies for generating therapeutic patient-specific hemangioblasts and hematopoietic stem cells from human pluripotent stem cells.
Review in The International journal of developmental biology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 33 citations in OpenAlex.
- Doping of Hollow Urchin-like MnOInternational journal of molecular sciences · 2025Article
- Review
- Running the full human developmental clock in interspecies chimeras using alternative human stem cells with expanded embryonic potential.NPJ Regenerative medicine · 2021Review
- Mechanistic Analysis of Physicochemical Cues in Promoting Human Pluripotent Stem Cell Self-Renewal and Metabolism.International journal of molecular sciences · 2018Article
- Article
- Capturing Human Naïve Pluripotency in the Embryo and in the Dish.Stem cells and development · 2017Review
- The role of Wnt signaling in hematopoietic stem cell development.Critical reviews in biochemistry and molecular biology · 2017Review
- SOX17 Regulates Conversion of Human Fibroblasts Into Endothelial Cells and Erythroblasts by Dedifferentiation Into CD34Circulation · 2017Article
- Enrichment of Scleroderma Vascular Disease-Associated Autoantigens in Endothelial Lineage Cells.Arthritis & rheumatology (Hoboken, N.J.) · 2016Article
- Endothelial Progenitor Cells in Diabetic Microvascular Complications: Friends or Foes?Stem cells international · 2016Review
- Lost in translation: pluripotent stem cell-derived hematopoiesis.EMBO molecular medicine · 2015Review
- Differentiation potential of o bombay human-induced pluripotent stem cells and human embryonic stem cells into fetal erythroid-like cells.Cell journal · 2015Article
- Local Renin-Angiotensin system in normal hematopoietic and multiple myeloma-related progenitor cells.Turkish journal of haematology : official journal of Turkish Society of Haematology · 2014Article
- Vascular progenitors from cord blood-derived induced pluripotent stem cells possess augmented capacity for regenerating ischemic retinal vasculature.Circulation · 2014Article
- Signalling pathways that control vertebrate haematopoietic stem cell specification.Nature reviews. Immunology · 2013Review
- Local bone marrow Renin-Angiotensin system and atherosclerosis.Cardiology research and practice · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Recent characterization of hemangioblasts differentiated from human embryonic stem cells (hESC) has further confirmed evidence from murine, zebrafish and avian experimental systems that hematopoietic and endothelial lineages arise from a common progenitor. Such progenitors may provide a valuable resource for delineating the initial developmental steps of human hemato-endotheliogenesis, which is a process normally difficult to study due to the very limited accessibility of early human embryonic/fetal tissues. Moreover, efficient hemangioblast and hematopoietic stem cell (HSC) generation from patient-specific pluripotent stem cells has enormous potential for regenerative medicine, since it could lead to strategies for treating a multitude of hematologic and vascular disorders. However, significant scientific challenges remain in achieving these goals, and the generation of transplantable hemangioblasts and HSC derived from hESC currently remains elusive. Our previous work has suggested that the failure to derive engraftable HSC from hESC is due to the fact that current methodologies for differentiating hESC produce hematopoietic progenitors developmentally similar to those found in the human yolk sac, and are therefore too immature to provide adult-type hematopoietic reconstitution. Herein, we outline the nature of this challenge and propose targeted strategies for generating engraftable human pluripotent stem cell-derived HSC from primitive hemangioblasts using a developmental approach. We also focus on methods by which reprogrammed somatic cells could be used to derive autologous pluripotent stem cells, which in turn could provide unlimited sources of patient-specific hemangioblasts and HSC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.